Raymond James Financial Inc. Purchases Shares of 201,020 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Raymond James Financial Inc. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 201,020 shares of the medical equipment provider's stock, valued at approximately $21,234,000. Raymond James Financial Inc. owned about 0.10% of Zimmer Biomet at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the 4th quarter worth $25,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet in the fourth quarter worth about $39,000. OFI Invest Asset Management bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $40,000. SRS Capital Advisors Inc. increased its stake in Zimmer Biomet by 146.9% in the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after purchasing an additional 285 shares during the period. Finally, Atala Financial Inc purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $51,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Up 1.0 %

NYSE:ZBH traded up $0.96 on Thursday, reaching $100.41. 238,512 shares of the stock traded hands, compared to its average volume of 1,655,773. The company's fifty day simple moving average is $105.80 and its 200 day simple moving average is $106.57. The company has a market capitalization of $19.87 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 12 month low of $93.10 and a 12 month high of $123.96. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm posted $2.20 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.96%. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. JMP Securities reissued a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James cut their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada cut their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.